About the Transaction
Paramax advised Bureau Veritas SA (ENXTPA:BVI) on the acquisition of Advanced Testing Laboratory (“ATL”) (www.atlscience.com). ATL is a full-service provider of scientific testing functions for leading consumer goods as well as pharmaceutical and medical device companies, primarily in North America. Headquartered in Cincinnati, Ohio, ATL’s services span the entire product life cycle, from research and development to substance and product qualification to manufacturing. Services include Analytical Chemistry, Engineering, Life Science, Product Performance, Product Safety & Regulatory, Quality Assurance and Regulatory Compliance. ATL employs over 500 people across the United States and generates annualized revenue of approximately $40 million.
Bureau Veritas SA (ENXTPA:BVI) (“BV”) (www.bureauveritas.com) is a world leader in laboratory testing, inspection, and certification services. Founded in 1828, Bureau Veritas’ 80,000 employees serve a variety of industries including: Automotive, Transport & Aerospace, Buildings & Infrastructure, Commodities, Consumer Products & Retail, Cybersecurity, Agri-food, Oil & Gas, and Power & Utilities among others. Serving its 400,000+ customers from over 1,600 offices worldwide, Bureau Veritas helps its clients improve their performance by offering services and innovative solutions in order to ensure that their assets, products, infrastructure and processes meet standards and regulations in terms of quality, health and safety, environmental protection and social responsibility.
Didier Michaud-Daniel, Chief Executive Officer of Bureau Veritas, commented on the acquisition:
“In line with the company’s 2025 Strategy, BV is accelerating the diversification of its Consumer Products Services division into new markets and service models. Through its strong expertise in on-site scientific sourcing solutions and in lab-based services, the acquisition of ATL will contribute to the expansion of BV’s footprint in the North American Consumer Products and Consumer Healthcare markets. BV will now be able to offer a unique scientific sourcing, supply chain management and ESG solution to Consumer Healthcare Products and Medical Device brands.”
Paramax served as the exclusive M&A advisor to Bureau Veritas on this transaction.